Types of Medicine for Dementia and How They Work

Two classes of prescription drugs are currently approved to treat dementia symptoms in Alzheimer’s disease: cholinesterase inhibitors and the glutamate regulator memantine. Neither stops the disease from progressing, but both can modestly slow cognitive decline for a time. A newer wave of anti-amyloid antibody infusions, approved since 2023, represents the first medicines designed to alter the underlying disease biology rather than just manage symptoms. Beyond these, treatment options vary considerably depending on which type of dementia a person has, what behavioral symptoms are present, and how far the disease has advanced.

Cholinesterase Inhibitors and Memantine

The backbone of dementia treatment for over two decades has been a group of medicines that boost a brain chemical called acetylcholine, which is progressively lost as Alzheimer’s disease destroys neurons. Three cholinesterase inhibitors are FDA-approved: donepezil (for mild through severe Alzheimer’s), galantamine, and rivastigmine (both for mild to moderate Alzheimer’s). A fourth drug, memantine, works differently by regulating glutamate, another brain signaling chemical, and is approved for moderate to severe Alzheimer’s.¹

How much do these medications actually help? A Cochrane review of ten randomized trials found that six months of treatment with any of the three cholinesterase inhibitors produced a small but real improvement in cognitive test scores and in clinicians’ ratings of overall function. The review was blunt in noting that none of these effects are large.² A long-term registry study tracking thousands of patients over years found that cholinesterase inhibitor users showed a slightly slower rate of cognitive decline and had a roughly 27% lower risk of death compared with nonusers. Among the individual drugs, galantamine was linked to the strongest effect on cognition and the lowest mortality risk.³

Combining a cholinesterase inhibitor with memantine is common practice in moderate to severe Alzheimer’s and is generally well tolerated. Preclinical work suggests the two drug classes complement each other because they act on different chemical pathways involved in learning and memory.⁴ In clinical practice, the combination is sometimes described as the current standard of care for moderate to severe disease.⁵ That said, a meta-analysis of Alzheimer’s clinical trial data found that participants already taking these medications actually declined faster on cognitive tests than untreated participants in the same trials. The authors interpreted this not as evidence the drugs make things worse, but as a sign that people who are prescribed these drugs tend to have more advanced or aggressive disease to begin with.⁶ The honest summary is that these drugs provide a modest buffer against decline, not a cure.

Anti-Amyloid Antibodies

The biggest shift in Alzheimer’s treatment in the last few years has been the FDA approval of monoclonal antibodies designed to clear amyloid-beta protein from the brain. Three have received approval: aducanumab, lecanemab, and donanemab. Earlier antibodies that targeted only the harmless, free-floating form of amyloid failed to show clinical benefit. The newer generation targets the toxic clumped forms, and that distinction turned out to matter.⁷

Lecanemab is the best-studied of the group. In a large phase 3 trial of nearly 1,800 people with early Alzheimer’s, those receiving the drug showed about 27% less decline on a composite measure of cognition and daily function over 18 months compared with placebo. Brain scans confirmed a substantial reduction in amyloid plaque.⁸ That slowing is real and statistically meaningful, but it is also modest in absolute terms. Whether individual patients and their families notice the difference in daily life remains debated. These drugs are given as intravenous infusions, typically every two weeks, and they are approved only for people in the early stages of the disease.

One serious concern with this entire drug class is a side effect called amyloid-related imaging abnormalities, known by the acronym ARIA. ARIA shows up on MRI as either brain swelling or tiny brain bleeds. Most episodes are mild and resolve on their own, but severe cases can cause symptoms and, rarely, can be dangerous. The biggest risk factor is carrying a gene variant called APOE ε4. In one systematic review, people who carried two copies of that variant and received high-dose treatment had the highest rates of ARIA.⁹ Analysis of another anti-amyloid antibody, gantenerumab, confirmed that APOE ε4 homozygous carriers faced roughly a fivefold higher risk of brain swelling compared with noncarriers, and that preexisting cerebrovascular disease also increased risk.¹⁰ This means that before starting any of these antibody treatments, patients undergo genetic testing and regular MRI monitoring.

Getting the Right Diagnosis First

Anti-amyloid therapies only make sense for people who actually have amyloid buildup in their brains, and not everyone with memory loss does. Confirming that has traditionally required either an expensive PET scan or a lumbar puncture to test spinal fluid. Blood tests are now emerging that can streamline this process dramatically. A plasma test for a protein called p-tau217 has shown strong accuracy in identifying Alzheimer’s pathology in people with mild cognitive impairment, correctly categorizing about 80% of patients without needing further invasive testing.¹¹ In a study examining whether blood tests could replace brain scans for selecting patients for immunotherapy, p-tau217 performed best, with the potential to eliminate over half of the PET scans that would otherwise be needed.¹² This matters because expanding access to anti-amyloid drugs depends on having a way to identify the right patients without bottlenecking the system at the PET scanner.

When Dementia Is Not Alzheimer’s

Alzheimer’s disease accounts for the majority of dementia cases, but vascular dementia, Lewy body dementia, and frontotemporal dementia each present distinct treatment challenges. The drug options shrink considerably outside Alzheimer’s territory.

For vascular dementia, there is no FDA-approved medication specifically for the condition. Cholinesterase inhibitors and memantine are sometimes prescribed off-label, but the cognitive improvements tend to be small and inconsistent, and they do not improve overall clinical outcomes.¹³ A large network meta-analysis of 194 randomized trials found that some drugs performed better than others on cognitive scores in vascular dementia, with butylphthalide, huperzine A, and edaravone ranking among the most effective, though many of these studies were conducted in Chinese populations and may not generalize broadly.¹⁴ A more practical approach for vascular dementia focuses on prevention rather than treatment: controlling blood pressure, managing cholesterol with statins, and preventing recurrent strokes.¹⁵

Lewy body dementia responds to cholinesterase inhibitors somewhat better than vascular dementia does, but managing its psychiatric symptoms is tricky. Many people with Lewy body dementia experience vivid hallucinations and delusions, yet standard antipsychotic drugs can trigger severe, even life-threatening reactions in this population.¹⁶ This sensitivity to antipsychotics is one of the starkest examples of why getting the right diagnosis before prescribing matters.

Frontotemporal dementia is the hardest to treat pharmacologically. No approved drug targets its core pathology, and the proteins involved, mainly tau and TDP-43, are driven by mutations in genes that differ from those behind typical Alzheimer’s.¹⁷ Treatment in frontotemporal dementia is largely about managing behavioral symptoms with selective serotonin reuptake inhibitors and avoiding antipsychotics where possible.

Medicines for Behavioral and Sleep Symptoms

Agitation, aggression, psychosis, and sleep disruption are among the most distressing features of dementia, both for the person living with it and for caregivers. Antipsychotic drugs are frequently prescribed to manage these symptoms, but the evidence paints an uncomfortable picture. Systematic reviews find that antipsychotics produce only modest improvements in aggression and agitation while carrying real risks.¹⁸ A network meta-analysis comparing several atypical antipsychotics found that risperidone, aripiprazole, and quetiapine each showed small benefits on different behavioral measures, but risperidone and olanzapine were also linked to increased risk of cerebrovascular adverse events. No single drug stood out as both clearly effective and clearly safe.¹⁹

A large population-based study sharpened those safety concerns considerably. Compared with nonuse, antipsychotic prescriptions in people with dementia were associated with roughly double the risk of pneumonia, and elevated risks of stroke, blood clots, kidney injury, heart failure, and fractures.²⁰ The consensus from guidelines is that antipsychotics should be reserved for severe behavioral symptoms that have not responded to non-drug approaches, and used at the lowest dose for the shortest time possible.

Sleep problems are especially common in Alzheimer’s and can accelerate cognitive decline. A newer class of sleep medication called dual orexin receptor antagonists (DORAs) has attracted attention because it targets the brain’s wakefulness-promoting system without the sedative hangover of older sleep drugs. Clinical evidence supports their use for improving sleep quality in people with Alzheimer’s who also have sleep or circadian rhythm disorders.²¹ Animal studies have gone further, showing that these drugs reduce amyloid plaque and tau protein formation in the brain, raising the possibility that better sleep might directly slow disease pathology.²² Whether that translates to a meaningful disease-modifying effect in humans is still being tested.

Repurposed Drugs and the GLP-1 Connection

Some of the most intriguing signals in dementia treatment are coming from drugs that were never designed for the brain. GLP-1 receptor agonists, widely known as diabetes and weight-loss medications, have shown neuroprotective properties in preclinical research. They appear to improve insulin signaling in the brain, which is impaired in Alzheimer’s, and to reduce both amyloid plaque and abnormal tau protein in animal models.²³ The mechanism seems to involve compensating for the impaired insulin pathways that neurons depend on for energy, survival, and repair.²⁴

Large observational data has added weight to the preclinical findings. A propensity-matched cohort study found that obese patients treated with GLP-1 receptor agonists had roughly 37% lower risk of developing Alzheimer’s disease, about 41% lower risk of Lewy body dementia, and more than 56% lower risk of vascular dementia compared with matched controls.²⁵ Those are observational data, so they cannot prove cause and effect, and the study was in obese patients specifically. Randomized trials of semaglutide and other GLP-1 drugs for Alzheimer’s prevention and treatment are now underway, and the results will clarify whether the effect is real and how large it is.

Experimental Approaches Targeting Tau and Beyond

While anti-amyloid antibodies have dominated recent headlines, many researchers believe that tackling tau, the other hallmark protein in Alzheimer’s, is equally or more important. Tau tangles correlate more closely with symptom severity than amyloid plaques do, so reducing tau could directly protect neurons.

One promising approach is an antisense oligonucleotide called MAPTRx, which blocks the production of tau protein at the genetic level. In a phase 1b trial of people with mild Alzheimer’s, MAPTRx produced dose-dependent reductions in tau concentrations in spinal fluid. At higher doses, tau levels continued to drop even after treatment stopped, reaching reductions of more than 50% at 24 weeks after the last dose.²⁶ It is too early to know whether those biochemical reductions translate into cognitive benefit, but the magnitude of tau lowering is striking and has prompted larger trials.

Another experimental target involves a receptor on immune cells in the brain called TREM2. This receptor helps microglia, the brain’s resident immune cells, clear amyloid deposits and regulate inflammation. When TREM2 is not functioning properly, microglia lose their ability to clean up toxic proteins and can generate excessive inflammation that damages neurons.²⁷ Drugs that activate TREM2 are in clinical testing, though early results from a trial of one such drug were disappointing, highlighting how far this target still is from the clinic.

Gene therapy for Alzheimer’s remains in its earliest stages. Researchers have used viral vectors to deliver protective genes to the brains of mice. In one approach, delivering the gene for ApoE2 (a version of the ApoE protein associated with lower Alzheimer’s risk) to the brains of nonhuman primates via injection into spinal fluid produced widespread ApoE2 expression in brain regions relevant to the disease.²⁸ Other gene therapy strategies have targeted CD33, a molecule on immune cells that affects amyloid clearance, and successfully reduced amyloid levels in mouse brains.²⁹ These remain far from clinical use, but they represent a fundamentally different approach: instead of infusing a drug repeatedly, the idea is to deliver a one-time genetic instruction that the brain’s own cells carry out.

The Blood-Brain Barrier Problem

A persistent challenge across almost all dementia drugs is getting enough of the medicine into the brain. The blood-brain barrier is a tightly sealed layer of cells that lines the brain’s blood vessels and blocks most large molecules from entering. Antibody drugs like lecanemab are enormous molecules, roughly 300 times the size limit the barrier typically allows, and only about 0.1% of the infused dose reaches the brain.³⁰ This is one reason patients need large, frequent intravenous infusions.

Several strategies are being developed to overcome this. Focused ultrasound combined with microbubbles can temporarily and safely open the barrier in targeted brain regions. Receptor-mediated transcytosis engineers drugs to hitch a ride on natural transport systems that shuttle molecules across the barrier. And nanoparticle carrier systems package drugs in tiny particles designed to slip through or be actively pulled across.³¹ If any of these approaches work well in humans, they could transform the dosing and practicality of existing drugs as much as entirely new drugs would.

Why the Failure Rate Has Been So High

The history of dementia drug development is sobering. An analysis of roughly two decades of Alzheimer’s clinical trials found that 98 unique compounds failed in mid- and late-stage testing, giving the field a success rate of about 2%.³² That dismal track record explains why the recent anti-amyloid approvals, however modest their clinical effects, were greeted with such excitement. It also explains why the field is moving toward combination therapy rather than pinning hopes on any single mechanism.

The logic behind combination therapy is straightforward: Alzheimer’s involves amyloid buildup, tau tangles, inflammation, synapse loss, and metabolic dysfunction all at once. A single drug targeting one of those processes is unlikely to produce dramatic improvement. Researchers are now designing trials that combine anti-amyloid and anti-tau drugs, or pair anti-amyloid drugs with anti-inflammatory agents.³³ The aim is to hit multiple targets simultaneously, the way combination therapy transformed treatment in HIV and certain cancers.³⁴

The Cost and Access Problem

Even where effective treatments exist, getting them to patients is a separate challenge. Anti-amyloid antibody infusions require regular MRI monitoring, genetic testing, and infusion center visits over months or years. The drugs themselves are expensive. A modeling study across 174 countries found that value-based prices for lecanemab ranged from roughly $250 to $9,400 in high-income countries, but dropped to single digits in low-income countries when measured against what those health systems can afford.³⁵ A separate modeling study for the United States estimated that treating eligible patients with anti-amyloid therapy would generate over 222,000 quality-adjusted life years at a cost of about $29 billion. When the analysis factored in health equity, giving extra weight to improvements for people who are sickest, the benefit picture improved, but the costs remained enormous.³⁶

This gap between what exists in the lab and what reaches a patient in the clinic is widening. Blood biomarker tests for Alzheimer’s could help narrow it by making diagnosis cheaper and faster, but infusion infrastructure, specialist access, and drug pricing remain bottlenecks that no single technology fix will solve.

Medical Foods and Nutritional Approaches

A handful of products marketed as “medical foods” have claimed to offer cognitive benefits in Alzheimer’s. These sit in a regulatory gray zone: they are not drugs and do not go through the same approval process. Three have been marketed specifically for Alzheimer’s, each targeting a different proposed mechanism: one supplies ketone bodies as an alternative brain fuel, another provides nutrient precursors meant to support synapse function, and a third addresses oxidative stress linked to memory loss.³⁷

The evidence for these products is thin. A meta-analysis of randomized trials of Souvenaid, the synapse-support formula, found no significant differences from placebo on standard cognitive or functional measures. One individual trial did report a modest improvement in delayed verbal recall in a subgroup of people with very mild Alzheimer’s, but that benefit did not extend to broader cognitive or daily function scores.³⁸ Some families are drawn to these products because they are available without a prescription and feel like a low-risk option, but the current evidence does not support expecting meaningful cognitive benefits from them.

A more promising direction combines lifestyle interventions with pharmacological or nutritional approaches in a tailored way. Trials like MET-FINGER are testing whether pairing structured exercise, cognitive training, and dietary changes with repurposed drugs like metformin can prevent or slow cognitive impairment in people identified as being at high risk.³⁹ Early reviews of this precision-prevention approach suggest that well-designed interventions, matched to the right people at the right time, may improve cognition more consistently than any single pill alone.⁴⁰

1
PubMed. Combination therapy for Alzheimer’s disease ↩︎
2
Cochrane Database of Systematic Reviews. Cholinesterase inhibitors for Alzheimer’s disease ↩︎
3
PubMed Central. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality ↩︎
4
PubMed Central. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease ↩︎
5
PubMed. Combination therapy for Alzheimer’s disease ↩︎
6
JAMA Network Open. Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis ↩︎
7
PubMed Central. Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives ↩︎
8
PubMed. Lecanemab in Early Alzheimer’s Disease ↩︎
9
JAMA Neurology. Amyloid-Related Imaging Abnormalities and β-Amyloid–Targeting Antibodies: A Systematic Review ↩︎
10
JAMA Neurology. Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease ↩︎
11
PubMed Central. Blood biomarkers for Alzheimer’s disease in clinical practice and trials ↩︎
12
JAMA Neurology. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies ↩︎
13
Neurotherapeutics. Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications ↩︎
14
PubMed Central. Pharmacological treatments for vascular dementia: a systematic review and Bayesian network meta-analysis ↩︎
15
Neurotherapeutics. Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications ↩︎
16
PubMed. Dementia with Lewy bodies: review and pharmacotherapeutic implications ↩︎
17
PubMed Central. Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration ↩︎
18
PubMed Central. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses ↩︎
19
JAMA Network Open. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis ↩︎
20
BMJ. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study ↩︎
21
PubMed Central. Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer’s Disease and Associated Sleep Disorders ↩︎
22
PubMed Central. Effect of a dual orexin receptor antagonist on Alzheimer’s disease: Sleep disorders and cognition ↩︎
23
PubMed. The effects of GLP-1 receptor agonists on Alzheimer’s pathophysiology: A systematic review ↩︎
24
PubMed Central. Unlocking the Potential: Semaglutide’s Impact on Alzheimer’s and Parkinson’s Disease in Animal Models ↩︎
25
PubMed. Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study ↩︎
26
Nature Medicine. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial ↩︎
27
PubMed Central. The potential and challenges of TREM2-targeted therapy in Alzheimer’s disease: insights from the INVOKE-2 study ↩︎
28
PubMed Central. AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer’s Disease ↩︎
29
Human Molecular Genetics. Gene therapy for Alzheimer’s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation ↩︎
30
PubMed Central. Drug delivery strategies to cross the blood-brain barrier in Alzheimer’s disease: a comprehensive review on three promising strategies ↩︎
31
PubMed Central. Alzheimer’s disease and drug delivery across the blood–brain barrier: approaches and challenges ↩︎
32
PubMed Central. Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures ↩︎
33
PubMed Central. Challenges and opportunities for novel combination therapies in Alzheimer’s disease: a report from the EU/US CTAD Task Force ↩︎
34
PubMed Central. Alzheimer Combination Therapies: Overview and Scenarios ↩︎
35
PubMed Central. Value-based prices of emerging disease-modifying therapies for Alzheimer’s disease in 174 countries: a cost-effectiveness and threshold analysis ↩︎
36
PubMed Central. Modeling the Population Equity of Alzheimer Disease Treatments in the US ↩︎
37
PubMed Central. Use of medical foods and nutritional approaches in the treatment of Alzheimer’s disease ↩︎
38
PubMed. The efficacy of supplementation with the novel medical food, Souvenaid, in patients with Alzheimer’s disease: A systematic review and meta-analysis of randomized clinical trials ↩︎
39
PubMed Central. A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol ↩︎
40
PubMed Central. Risk reduction and precision prevention across the Alzheimer’s disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches ↩︎